Literature DB >> 12190289

P53 immunohistochemical expression: messages in cervical carcinogenesis.

Phaik-Leng Cheah1, Lai-Meng Looi.   

Abstract

AIMS: The pattern of p53 expression was studied in pre-invasive and invasive cervical carcinoma in an attempt to clarify its role in cervical carcinogenesis.
METHODS: A total of 234 invasive cervical carcinomas (152 squamous cell carcinomas, 61 adenocarcinomas and 21 adenosquamous carcinomas) and 16 cervical intraepithelial neoplasia (CIN) I, six CIN II and 25 CIN III were immunohistochemically studied for p53.
RESULTS: p53 was detected more frequently in CIN and invasive carcinoma (100% of CIN I, 74.2% CIN II + III and 70.1% invasive carcinoma) compared with benign cervices (P< 0.001); however, only three squamous cell carcinomas, 11 adenocarcinomas and two adenosquamous carcinomas exhibited p53 expression in >75% of tumour nuclei. Six of the 11 adenocarcinomas and both adenosquamous carcinomas were poorly differentiated compared with one of the three squamous carcinomas. p53 immunoreactive cells were randomly distributed in invasive carcinoma, confined to the lower third of the epithelium in CIN I, reached the middle third in 20% of CIN II and upper third in 16.6% of CIN III.
CONCLUSIONS: Assuming that p53 immunoreactivity indicates gene mutation when the majority (> 75%) of neoplastic cells express p53, p53 mutations would seem uncommon in cervical carcinogenesis. Nonetheless, glandular malignancies, in particular poorly differentiated variants, may show a higher frequency of mutation. p53 was detected more frequently in CIN I compared with CIN II/III and invasive carcinoma which may be due to p53 protein degradation following interaction with high risk human papillomavirus E6 protein in CIN II/III and invasive carcinoma.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12190289     DOI: 10.1080/003130202760120472

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  3 in total

1.  High-risk human papillomavirus in non-melanoma skin lesions from renal allograft recipients and immunocompetent patients.

Authors:  M Reuschenbach; T Tran; F Faulstich; W Hartschuh; S Vinokurova; M Kloor; E Krautkrämer; M Zeier; M von Knebel Doeberitz; C Sommerer
Journal:  Br J Cancer       Date:  2011-03-22       Impact factor: 7.640

2.  Tumourigenesis driven by the human papillomavirus type 16 Asian-American e6 variant in a three-dimensional keratinocyte model.

Authors:  Robert Jackson; Melissa Togtema; Paul F Lambert; Ingeborg Zehbe
Journal:  PLoS One       Date:  2014-07-01       Impact factor: 3.240

3.  p53 and bcl2 expression in malignant and premalignant lesions of uterine cervix and their correlation with human papilloma virus 16 and 18.

Authors:  Shailaja Shukla; Jasmita Dass; Mukta Pujani
Journal:  South Asian J Cancer       Date:  2014-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.